Achilles Therapeutics plc (ACHL)
| Market Cap | 60.83M |
| Revenue (ttm) | n/a |
| Net Income | -66.88M |
| EPS | -1.66 |
| Shares Out | 41.10M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.480 |
| Previous Close | 1.480 |
| Day's Range | 1.480 - 1.480 |
| 52-Week Range | 0.680 - 1.510 |
| Beta | 1.25 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2025 |
About ACHL
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic o... [Read more]
Financial Performance
Financial StatementsNews
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
- Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction -
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nas...
Achilles Therapeutics Reports Third Quarter 2024 Financial Results
– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –
Achilles Therapeutics Announces Strategic Update
–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities engaged to provide strategic financial advice– LONDON, Sep...
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles' AI-powered, tumor-targeting technology –
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
Research collaboration combines Achilles' best-in-class AI-driven, tumor-targeting technology with Arcturus' world-leading self-amplifying mRNA platform
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company's operations are not affected by the receipt of the Notice Achilles ADSs will continue to trade on...
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host conditioning with further data expected in 2H 202...
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated ...
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three ...
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoanti...
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies Newly developed computational tools and large ...
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1 202...
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma -
Achilles Therapeutics to Present at Upcoming Conferences
LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, t...
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
- Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of 2023 -
Achilles Therapeutics' New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
- New AI module delivers a "Target-to-T cell” approach for revolutionizing the identification and prioritization of targets for personalized antigen approaches - - New AI module delivers a "Target-to-...
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
- Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a patient's tumor -
Achilles Therapeutics to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
LONDON, April 17, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, ...
Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights
- Demonstrated early proof-of-concept for cNeT therapy in heavily pre-treated advanced NSCLC patients -
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
LONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, t...
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
- Early proof-of-concept data support durable clinical benefit including confirmed partial response and stable disease in heavily pre-treated patients with advanced NSCLC -
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy -
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
- US patent is for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE), including vaccine, antibody, and autologous T cell therapy approaches - - US patent ...
Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
- Interim update from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) to be presented at the ESMO Immuno-Oncology Annual Congress 2022 -